CANDEL THERAPEUTICS I

Candel Therapeutics to Present at Jefferies London Healthcare Conference 2024

07 11 2024 08:00:01 提供 Nasdaq GlobeNewswire

Candel Therapeutics to Present Preclinical Data at SITC Annual Meeting Showing Promise for CAN-3110 in Melanoma, Signaling Potential Indication Expansion Beyond Recurrent High-Grade Glioma

05 11 2024 09:00:32 提供 Nasdaq GlobeNewswire

Candel Therapeutics Showcases Innovative Cancer Therapy Candidates at 16th Annual International Oncolytic Virotherapy Conference (IOVC)

28 10 2024 08:00:00 提供 Nasdaq GlobeNewswire

Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting

04 10 2024 09:00:45 提供 Nasdaq GlobeNewswire

Candel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference

03 9 2024 08:00:00 提供 Nasdaq GlobeNewswire

Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

13 8 2024 08:00:01 提供 Nasdaq GlobeNewswire

Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

18 6 2024 08:00:00 提供 Nasdaq GlobeNewswire

Candel Therapeutics to Join Russell 3000® Index

11 6 2024 08:00:00 提供 Nasdaq GlobeNewswire

FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma

30 5 2024 08:00:00 提供 Nasdaq GlobeNewswire

Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting

23 5 2024 17:00:00 提供 Nasdaq GlobeNewswire

Candel Therapeutics to Present at the Jefferies Global Healthcare Conference

22 5 2024 08:00:00 提供 Nasdaq GlobeNewswire

Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting

20 5 2024 08:00:00 提供 Nasdaq GlobeNewswire

Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

14 5 2024 08:00:00 提供 Nasdaq GlobeNewswire

Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting

25 4 2024 08:00:00 提供 Nasdaq GlobeNewswire

Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer

11 4 2024 09:00:00 提供 Nasdaq GlobeNewswire

Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors

09 4 2024 08:00:00 提供 Nasdaq GlobeNewswire

Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

04 4 2024 08:00:00 提供 Nasdaq GlobeNewswire

Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma

28 3 2024 16:05:00 提供 Nasdaq GlobeNewswire

Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights

28 3 2024 08:05:47 提供 Nasdaq GlobeNewswire

Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate

05 3 2024 16:30:00 提供 Nasdaq GlobeNewswire